Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway Sells 8,748 Shares

Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Jean F. Holloway sold 8,748 shares of the firm's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $29.00, for a total transaction of $253,692.00. Following the sale, the senior vice president now owns 178,510 shares of the company's stock, valued at approximately $5,176,790. This represents a 4.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Artivion Stock Down 0.4%

Shares of Artivion stock traded down $0.13 during trading on Friday, reaching $29.58. 463,268 shares of the company traded hands, compared to its average volume of 330,037. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $32.33. The company has a 50 day moving average price of $25.62 and a 200-day moving average price of $27.39. The firm has a market capitalization of $1.26 billion, a PE ratio of -1,479.00 and a beta of 1.54.

Artivion (NYSE:AORT - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.12 by ($0.06). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $98.98 million for the quarter, compared to analyst estimates of $94.81 million. As a group, equities research analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Artivion

Several hedge funds and other institutional investors have recently made changes to their positions in AORT. Next Century Growth Investors LLC increased its position in shares of Artivion by 107.6% during the first quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company's stock worth $25,140,000 after acquiring an additional 530,122 shares in the last quarter. Peregrine Capital Management LLC purchased a new position in Artivion during the first quarter worth about $7,650,000. Wasatch Advisors LP boosted its holdings in Artivion by 27.7% during the fourth quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company's stock worth $29,791,000 after purchasing an additional 226,160 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Artivion during the fourth quarter worth about $5,573,000. Finally, First Trust Advisors LP purchased a new position in Artivion during the fourth quarter worth about $4,771,000. 86.37% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have weighed in on AORT. JMP Securities reiterated a "market outperform" rating and issued a $33.00 price objective on shares of Artivion in a research note on Tuesday, May 6th. Citizens Jmp raised shares of Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. Stifel Nicolaus decreased their target price on shares of Artivion from $33.00 to $30.00 and set a "buy" rating on the stock in a report on Tuesday, February 25th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $32.00 target price on shares of Artivion in a report on Tuesday, May 6th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Artivion currently has a consensus rating of "Buy" and an average price target of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.